No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 193 | 112 | 54 | 37 | 36 | 41 | N/A | N/A |
| Operating profit | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | €m | 23 | 2 | -6 | 13 | -6 | -0 | N/A | N/A |
| EPS reported | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Euromedis Groupe, a French company established in 1985 and based in Mouy, France, specializes in the development, manufacturing, and distribution of medical equipment. Operating under its proprietary Euromedis brand, the company caters to a broad clientele in France, including medical professionals, local public services, and private individuals. Its extensive product line encompasses a wide array of medical supplies. This includes sterile and non-sterile gloves, wound care essentials like dressings and compresses, and various medical kits. For parenteral care, it provides items such as needles, syringes, infusers, and catheters. The surgical range is comprehensive, featuring wound drainage products, probes, draping solutions for operating theaters, surgical gloves, and protective covers. Beyond these, Euromedis also offers oxygen therapy equipment, products for continence management and general hygiene, diagnostic tools, and a selection of home care necessities. In addition to its product offerings, Euromedis Groupe provides services such as the distribution and rental of medical equipment, as well as specialized in-home infusion and nutrition support. While primarily focused on the French market, the company has a significant international footprint, exporting its products to numerous countries including Belgium, Italy, Morocco, Ivory Coast, Gabon, Benin, Algeria, Ireland, the Netherlands, Portugal, Tunisia, Switzerland, the Czech Republic, the United Kingdom, Germany, Finland, Spain, Greece, Hungary, Lithuania, Latvia, Bulgaria, and Poland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Euromedis Groupe, a French company established in 1985 and based in Mouy, France, specializes in the development, manufacturing, and distribution of medical equipment. Operating under its proprietary Euromedis brand, the company caters to a broad clientele in France, including medical professionals, local public services, and private individuals. Its extensive product line encompasses a wide array of medical supplies. This includes sterile and non-sterile gloves, wound care essentials like dressings and compresses, and various medical kits. For parenteral care, it provides items such as needles, syringes, infusers, and catheters. The surgical range is comprehensive, featuring wound drainage products, probes, draping solutions for operating theaters, surgical gloves, and protective covers. Beyond these, Euromedis also offers oxygen therapy equipment, products for continence management and general hygiene, diagnostic tools, and a selection of home care necessities. In addition to its product offerings, Euromedis Groupe provides services such as the distribution and rental of medical equipment, as well as specialized in-home infusion and nutrition support. While primarily focused on the French market, the company has a significant international footprint, exporting its products to numerous countries including Belgium, Italy, Morocco, Ivory Coast, Gabon, Benin, Algeria, Ireland, the Netherlands, Portugal, Tunisia, Switzerland, the Czech Republic, the United Kingdom, Germany, Finland, Spain, Greece, Hungary, Lithuania, Latvia, Bulgaria, and Poland.
